Your session is about to expire
← Back to Search
Ophthalmic Solution
A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure
Phase 2
Waitlist Available
Research Sponsored by VivaVision Biotech, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8am, 10am, and 4pm at day 7; day 14 and day 21
Summary
This trial is testing VVN539, a medication aimed at lowering eye pressure, in patients with high eye pressure due to POAG or OHT. The medication works by affecting fluid production or drainage in the eye.
Eligible Conditions
- Primary Open Angle Glaucoma
- Open-Angle Glaucoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 8am, 10am, and 4pm at day 7; day 14 and day 21
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8am, 10am, and 4pm at day 7; day 14 and day 21
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Mean Intraocular Pressure
Secondary study objectives
Mean Change in Intraocular Pressure From Baseline
Trial Design
3Treatment groups
Active Control
Placebo Group
Group I: VVN539 Ophthalmic Solution 0.02%Active Control1 Intervention
VVN539 Ophthalmic Solution 0.02%
Group II: VVN539 Ophthalmic Solution 0.04%Active Control1 Intervention
VVN539 Ophthalmic Solution 0.04%
Group III: VVN539 Ophthalmic Solution VehiclePlacebo Group1 Intervention
VVN539 Ophthalmic Solution Vehicle
Find a Location
Who is running the clinical trial?
VivaVision Biotech, IncLead Sponsor
4 Previous Clinical Trials
1,080 Total Patients Enrolled
Xiao-Yan Li, M.D.Study DirectorVivaVision